As the largest publicly traded U.S. healthcare enterprise, Eli Lilly & Co. (NYSE:LLY) has historically offered investors a reliable avenue for growth. Indeed, this narrative has been particularly powerful in 2023 and 2024, which saw LLY stock rise from around $360 to approximately $960 in late summer of last year. However, amid a challenging environment in healthcare, LLY presents both opportunities and risks.
Fundamentally, Eli Lilly represents a juggernaut in medical innovations. Recently, the company has taken a leadership role in the diabetes and obesity space with therapeutics such as Zepbound and Trulicity. It has also moved into breast cancer treatment with Verzenio. As well, its researchers have targeted autoimmune diseases like psoriasis with the drug Taltz.
